4 recherche sur le mot-clé 'antipsychotic'

Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 [article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [texte imprimé] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294 Mots-clés : Autism  Autism spectrum disorder  Metformin  Antipsychotic  Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314

Safer and targeted use of antipsychotics in youth: an embedded, pragmatic randomized trial / Abisola E. IDU ; R. Yates COLEY ; Kara L. CUSHING-HAUGEN ; Deborah KING ; Ashley GLASS ; Rebecca PHILLIPS ; Anne D. RENZ ; Chester J. PABINIAK ; Vina F. GRAHAM ; Ella E. THOMPSON ; James D. RALSTON ; Gregory SIMON ; Erin S. GONZALEZ ; Kathleen M. MYERS ; Arne BECK ; LeeAnn M. QUINTANA ; Arthur J. RUNKLE ; Megan ROGERS ; Deirdre M. FOSTER ; Gregory N. CLARKE ; Stefan MASSIMINO ; Phillip M. CRAWFORD ; Julie A. CAVESE ; Anthony R. CORDARO ; Laura I. CHAVEZ ; Kelly J. KELLEHER ; Nadine SCHWARTZ ; Kristina R. JINER ; Swan Bee LIU ; Sara CONDRAC ; Robert HILT in Journal of Child Psychology and Psychiatry, 66-3 (March 2025)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 66-3 (March 2025) . - p.301-310 Titre : Safer and targeted use of antipsychotics in youth: an embedded, pragmatic randomized trial Type de document : texte imprimé Auteurs : Abisola E. IDU, Auteur ; R. Yates COLEY, Auteur ; Kara L. CUSHING-HAUGEN, Auteur ; Deborah KING, Auteur ; Ashley GLASS, Auteur ; Rebecca PHILLIPS, Auteur ; Anne D. RENZ, Auteur ; Chester J. PABINIAK, Auteur ; Vina F. GRAHAM, Auteur ; Ella E. THOMPSON, Auteur ; James D. RALSTON, Auteur ; Gregory SIMON, Auteur ; Erin S. GONZALEZ, Auteur ; Kathleen M. MYERS, Auteur ; Arne BECK, Auteur ; LeeAnn M. QUINTANA, Auteur ; Arthur J. RUNKLE, Auteur ; Megan ROGERS, Auteur ; Deirdre M. FOSTER, Auteur ; Gregory N. CLARKE, Auteur ; Stefan MASSIMINO, Auteur ; Phillip M. CRAWFORD, Auteur ; Julie A. CAVESE, Auteur ; Anthony R. CORDARO, Auteur ; Laura I. CHAVEZ, Auteur ; Kelly J. KELLEHER, Auteur ; Nadine SCHWARTZ, Auteur ; Kristina R. JINER, Auteur ; Swan Bee LIU, Auteur ; Sara CONDRAC, Auteur ; Robert HILT, Auteur Article en page(s) : p.301-310 Langues : Anglais (eng) Mots-clés : Antipsychotic  guidelines  consulting  accessibility Index. décimale : PER Périodiques Résumé : Background Antipsychotic medications (AP) are inappropriately prescribed to young people. The goal of this pragmatic trial was to test a four-component approach to improved targeting of antipsychotic prescribing to people aged 3 and <18 years. Methods Clinicians in four health systems were cluster randomized by the number of previous AP orders and service line ? specialty mental health and all others. Intervention arm clinicians received a best practice alert and child psychiatrist consultation and feedback. Families received system navigation and expedited access to psychotherapy. Primary outcomes were total days' supply of AP medication and proportion of youth with any AP supply at 6 months. We estimated the log-odds of AP use at 6 months and the relative rate of AP over 6 months. The Safer and Targeted Use of Antipsychotics in Youth (SUAY) trial took place between 3/2018 and 12/2020. Results The trial enrolled 733 patients. The odds ratio (OR) comparing use at 6 months was 0.75 (95% CI: 0.52, 1.09). The mean number of days using AP was 118.5 for intervention patients and 128.2 for control patients (relative risk [RR] 0.92; 95% CI: 0.81 1.04). Exploratory heterogeneity of treatment effects (HTE) was not detected in groups defined by age, gender, provider specialty, and insurance type. HTE by race/ethnicity was present: among youth of color, mean days' supply was 103.2 for intervention arm and 131.2 for the control arm (RR 0.79, 95% CI: 0.67 0.93). Among secondary outcomes, only new psychotherapy referrals differed with 44.3% (n 154) of intervention participants having a new order for psychotherapy compared to 33.5% (n 129) in the control arm (OR 1.47: 95% CI: 1.01 2.14). Conclusions This intervention did not result in less AP use at 6 months or a reduction in the days' supply of AP medication, although psychotherapy orders increased. The intervention may be effective for some subgroups. En ligne : https://doi.org/10.1111/jcpp.14059 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=548 [article] Safer and targeted use of antipsychotics in youth: an embedded, pragmatic randomized trial [texte imprimé] / Abisola E. IDU, Auteur ; R. Yates COLEY, Auteur ; Kara L. CUSHING-HAUGEN, Auteur ; Deborah KING, Auteur ; Ashley GLASS, Auteur ; Rebecca PHILLIPS, Auteur ; Anne D. RENZ, Auteur ; Chester J. PABINIAK, Auteur ; Vina F. GRAHAM, Auteur ; Ella E. THOMPSON, Auteur ; James D. RALSTON, Auteur ; Gregory SIMON, Auteur ; Erin S. GONZALEZ, Auteur ; Kathleen M. MYERS, Auteur ; Arne BECK, Auteur ; LeeAnn M. QUINTANA, Auteur ; Arthur J. RUNKLE, Auteur ; Megan ROGERS, Auteur ; Deirdre M. FOSTER, Auteur ; Gregory N. CLARKE, Auteur ; Stefan MASSIMINO, Auteur ; Phillip M. CRAWFORD, Auteur ; Julie A. CAVESE, Auteur ; Anthony R. CORDARO, Auteur ; Laura I. CHAVEZ, Auteur ; Kelly J. KELLEHER, Auteur ; Nadine SCHWARTZ, Auteur ; Kristina R. JINER, Auteur ; Swan Bee LIU, Auteur ; Sara CONDRAC, Auteur ; Robert HILT, Auteur . - p.301-310. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 66-3 (March 2025) . - p.301-310 Mots-clés : Antipsychotic  guidelines  consulting  accessibility Index. décimale : PER Périodiques Résumé : Background Antipsychotic medications (AP) are inappropriately prescribed to young people. The goal of this pragmatic trial was to test a four-component approach to improved targeting of antipsychotic prescribing to people aged 3 and <18 years. Methods Clinicians in four health systems were cluster randomized by the number of previous AP orders and service line ? specialty mental health and all others. Intervention arm clinicians received a best practice alert and child psychiatrist consultation and feedback. Families received system navigation and expedited access to psychotherapy. Primary outcomes were total days' supply of AP medication and proportion of youth with any AP supply at 6 months. We estimated the log-odds of AP use at 6 months and the relative rate of AP over 6 months. The Safer and Targeted Use of Antipsychotics in Youth (SUAY) trial took place between 3/2018 and 12/2020. Results The trial enrolled 733 patients. The odds ratio (OR) comparing use at 6 months was 0.75 (95% CI: 0.52, 1.09). The mean number of days using AP was 118.5 for intervention patients and 128.2 for control patients (relative risk [RR] 0.92; 95% CI: 0.81 1.04). Exploratory heterogeneity of treatment effects (HTE) was not detected in groups defined by age, gender, provider specialty, and insurance type. HTE by race/ethnicity was present: among youth of color, mean days' supply was 103.2 for intervention arm and 131.2 for the control arm (RR 0.79, 95% CI: 0.67 0.93). Among secondary outcomes, only new psychotherapy referrals differed with 44.3% (n 154) of intervention participants having a new order for psychotherapy compared to 33.5% (n 129) in the control arm (OR 1.47: 95% CI: 1.01 2.14). Conclusions This intervention did not result in less AP use at 6 months or a reduction in the days' supply of AP medication, although psychotherapy orders increased. The intervention may be effective for some subgroups. En ligne : https://doi.org/10.1111/jcpp.14059 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=548

Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders / Selma TURAL HESAPCIOGLU in Research in Autism Spectrum Disorders, 72 (April 2020)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 72 (April 2020) . - p.101520 Titre : Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders Type de document : texte imprimé Auteurs : Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu Pınar SEN, Auteur Article en page(s) : p.101520 Langues : Anglais (eng) Mots-clés : Antipsychotic  Aripiprazole  Autism Spectrum Disorders  Irritability  Olanzapine  Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5−10 mg/day) in comparison with 42 risperidone (1−4 mg/day) and 40 aripiprazole (3−15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 [article] Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders [texte imprimé] / Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu Pınar SEN, Auteur . - p.101520. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101520 Mots-clés : Antipsychotic  Aripiprazole  Autism Spectrum Disorders  Irritability  Olanzapine  Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5−10 mg/day) in comparison with 42 risperidone (1−4 mg/day) and 40 aripiprazole (3−15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421

Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder / Covadonga M. DIAZ-CANEJA in Journal of Child Psychology and Psychiatry, 55-9 (September 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Titre : Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder Type de document : texte imprimé Auteurs : Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur Article en page(s) : p.959-980 Langues : Anglais (eng) Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238 [article] Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder [texte imprimé] / Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur . - p.959-980. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238